Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 3Leukemia, Biphenotypic, Acute 2Sarcoma, Myeloid 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Monocytic, Acute 1Leukemia, Lymphoid 1Hematologic Neoplasms 1Desmoplastic Small Round Cell Tumor 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Ifosfamide 5Temozolomide 4surufatinib 2irinotecan sucrosofate 2Vincristine 2Radiotherapy 2Nivolumab 2Irinotecan 2Gemcitabine 2Etoposide 2Doxorubicin 2vactosertib 1temsirolimus 1talazoparib 1silmitasertib 1selinexor 1regorafenib 1pepinemab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1pazopanib 1olaparib 1lutetium Lu 177 dotatate 1liposomal doxorubicin 1lenvatinib 1etoposide phosphate 1endostar protein 1dostarlimab 1dinutuximab 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Osteosarcoma × pegylated granulocyte colony-stimulating factor × Clear all
NCT06709495 2026-02-19

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
63 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡